非唑奈坦的适应症

Fizolinant is a new type of non-hormonal drug developed by Japan's Astellas Pharmaceuticals, with the trade name Veozah. The drug was approved by the US FDA in 2023 for the treatment of moderate to severe vasomotor symptoms caused by menopause. As the first NK3 receptor antagonist, filazonatant provides a new treatment option for menopausal women. This article will introduce in detail the indications, efficacy, effects, and contraindications of fezonatant to help readers understand this innovative drug.

Indications of Fezonatan

It has clear clinical indications, mainly targeting menopausal symptoms in specific groups of people.

Main treatment scope

Fezonatant is specifically used to treat moderate to severe vasomotor symptoms caused by menopause, including hot flashes, night sweats and other common menopausal symptoms.

Applicable population characteristics

This drug is suitable for female patients with natural or surgical menopause. Clinical studies have shown that fezonatant can effectively improve vasomotor symptoms in female patients aged 45-65 years.

Fezonatant has clear indications and is highly targeted, providing a new solution for the treatment of menopausal symptoms.

Efficacy and role of filazonatant

Fezonatant exerts its therapeutic effect through a unique mechanism of action, which has advantages that are different from traditional hormone therapy.

Pharmacological mechanism of action

As an NK3 receptor antagonist, fizolinantine modulates the hypothalamic temperature regulation center function by blocking the neurokinin B signaling pathway. This mechanism of action is different from traditional hormone replacement therapy.

Clinical treatment effect

Daily administration of 45 mg of filazonatan can significantly reduce the frequency and severity of hot flashes. Clinical trial data show that after 12 weeks of taking the drug, patients had fewer hot flashes per week.

Characteristics of onset of action

The drug is rapidly absorbed after oral administration, with a median peak time of 1.5 hours. The half-life is about 9.6 hours, suitable for once-daily dosing regimen and easy to use.

Fezonatant exerts its efficacy through an innovative mechanism, providing an effective option for the management of menopausal symptoms.

Contraindications of filzonetant

Fezolinantant is not suitable for all people, and there are clear contraindications for its use.

Contraindications related to liver function

Contraindicated in patients with severe liver damage, including patients with Child-Pugh Class C liver damage and cirrhosis. Liver function tests must be performed before taking the drug. Use is prohibited for those with ALT or AST ≥ 2 times the upper limit of normal values.

Contraindications related to renal function

Contraindicated in patients with severe renal impairment, including patients with renal insufficiency and end-stage renal disease with eGFR<30ml/min/1.73m².

Drug interaction contraindications

It is prohibited to use it in combination with CYP1A2 inhibitors. These drugs will increase the plasma concentration of fezonatant and may aggravate adverse reactions.

Patients should understand the contraindications of fezonatant before taking the drug and use it under the guidance of a doctor.